Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from argenx

Biotech Leader Argenx In Buy Zone, Poised To Hit New Highs

Argenx stock is in a buy zone on the stock market today after a recent breakout and the biotech leader is poised to hit new highs.

Investors Business Daily

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

Investors Business Daily

Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval

Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay

Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."

Investors Business Daily

Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump

Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.

Investors Business Daily

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.

Investors Business Daily

Top Biotech 3 Stocks With Accelerating Profits

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Argenx Crashes 25% As The Setbacks Mount For Its Hallmark Drug, Vyvgart

Argenx stock crashed early Wednesday after its treatment for an autoimmune disease that causes skin blisters flopped in a Phase 3 study.

Investors Business Daily

Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review

The Dow Jones pushed higher, but the Nasdaq slipped despite strong software earnings and a Fed shift toward rate cuts. Tesla Cybertruck deliveries began.

Investors Business Daily

Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug

Argenx stock plummeted Tuesday after the company's drug unexpectedly failed to help patients with a rare blood disorder.

Investors Business Daily

Argenx Posts Strong Results For 'Seventh Straight Quarter Of Outperformance'

Argenx put up another strong quarter for immunology drug Vyvgart on Tuesday, but the biotech stock pulled back from bullish gains.

Investors Business Daily

Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.

Investors Business Daily

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering

Immunovant stock reversed lower Wednesday after the company announced a $300 million offering. IMVT stock almost doubled Tuesday.

Investors Business Daily

Immunovant Doubles — And Slugs Argenx — As Autoimmune Disease Battle Heats Up

Immunovant said Tuesday its experimental drug lowered an antibody tied to autoimmune diseases and IMVT stock launched.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Rise Ahead Of Fed Decision; Tesla Leads 12 Stocks To Watch

The market rally lost ground but avoided a highly bearish signal with the Fed decision on tap. Tesla stock is one to watch.

Investors Business Daily

New S&P 500 Entrant Airbnb And DKNG Lead 5 Stocks Near Buy Points

Airbnb, which is set to join the S&P 500 on Monday, and DKNG lead a watch list of stocks poised to make moves if the stock market can find its footing.

Investors Business Daily

How IBD Stock Of The Day Argenx, A Top-Notch Biotech, Is Dominating — With One Drug

Argenx is Friday's IBD Stock Of The Day. The biotech stock is climbing the right side of a cup base on enthusiasm for its drug, Vyvgart.

Investors Business Daily

Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market

AI stock standout Arista Networks and Netherlands-based biotech Argenx lead this weekend's watch list of 5 stocks holding in or near buy range.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Argenx Beats Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260%

Argenx is up around 40% in 2023. On Thursday, the company reported second-quarter revenue ballooning 230% as sales of its lone product ramp up.

Investors Business Daily

Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review

The Dow Jones lead the market rally, while Tesla, Netflix and Taiwan Semiconductor hit growth stocks Thursday.

Investors Business Daily

The Multibillion-Dollar Opportunity That Sent Argenx Flying 28% Into A Breakout

An Argenx drug beat expectations in a study of patients with a progressive nerve disorder and ARGX stock catapulted to a record high.

Barchart

Chart of the Day: Argenx - Great Biotech

The Chart of the Day belongs to the biotechnology company Argenx (ARGX) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature...

Investors Business Daily

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

Upgrades

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations